Noom Stock Price, Valuation & IPO
Private company — Noom is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$12.17 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 17 November 2026
Last round valuation: $3.7B
Source: F, May 2021, post-money
Total raised: $650+M
Data last updated: 17 November 2026
About Noom
Noom — a subscription-based weight loss app, founded in 2008 in Princeton by Saeju Jeong and Artem Petakov, a former Google Maps engineer. Since 2017, the company has been selling a weight loss program built on habit psychology, and since September 2024, its online doctors have been prescribing GLP-1 medications; in April 2026, Noom acquired its own pharmacy operating in 46 states. The essence of the model is in the combination: medications like Ozempic reduce weight, but after discontinuation, most regain more than half of the lost weight within a year, while Noom participants regain three times less. The GLP-1Rx line reached an annual revenue run rate of $100 million several months after launch, and since January 2026, insurer Highmark has opened programs to nearly 2 million of its clients. A total of over $650 million has been raised, with the latest valuation at $3.7 billion.
- Sector: Health & Pharma
Key highlights
- Highmark: programs opened 2 million clients. A Pennsylvania insurer announced a partnership in October 2025. Starting January 1, 2026, its overweight clients will receive weight and diabetes prevention programs as part of their insurance coverage at no additional cost.
- SmartRx: employer GLP-1 costs are 80% lower. According to Q1 2026 data, the first participating employer's annual spending on drugs will decrease from $6.2 million to $1.3 million: SmartRx buys brand-name drugs directly, bypassing pharmacy benefit intermediaries.
- Solera Health: Noom in a network of 30+ programs. Solera matches insured individuals with one of thirty digital programs and gets paid for the outcome. From September 2026, Noom joins the network, GLP-1 medication management support is free for participants.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 25 May 2021 | F | $60.34 | $3.7B |
| 6 May 2019 | E | $6.12 | $306M |
Frequently asked questions
How can I buy Noom stock before the IPO?
Not on a public exchange — Noom is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Noom stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $12.17 per share as of 17 November 2026. Its most recent round implied a post-money valuation of $3.7B (May 2021).
What is Noom's valuation (net worth)?
Noom's most recent funding round valued the company at $3.7B post-money (May 2021) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Noom IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Noom publicly traded?
No. Noom is a private company and its shares are not listed on any public exchange.
Does Noom have a stock symbol?
No. Noom has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Orca Bio — Health & Pharma
- Zocdoc — Health & Pharma
- Spring Health — Health & Pharma
- Ayar Labs — Semiconductors
- Chainguard — Cybersecurity
- Chai Discovery — Healthcare & Biotech
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.